Key statistics
On Friday, Assembly Biosciences Inc (V7B:FRA) closed at 21.50, -35.82% below its 52-week high of 33.50, set on Nov 21, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 21.50 |
|---|---|
| High | 21.50 |
| Low | 21.50 |
| Bid | -- |
| Offer | -- |
| Previous close | 21.90 |
| Average volume | 2.36k |
|---|---|
| Shares outstanding | 15.82m |
| Free float | 10.71m |
| P/E (TTM) | -- |
| Market cap | 421.68m USD |
| EPS (TTM) | -4.81 USD |
Data delayed at least 15 minutes, as of Feb 13 2026 07:00 GMT.
More ▼
Announcements
- Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes
- Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates
- Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®
- Assembly Biosciences Announces Upcoming Investor Conference Participation
- Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe
- Assembly Biosciences Announces Pricing of $175 Million in Equity Financings
- Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes
- Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
- Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates
- Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop
More ▼
